Kan mineraltilskud med bismuth mindske toksiciteten af kemoterapi og strålebehandling? En klinisk prospektiv, dobbeltblind randomiseret undersøgelse af patienter med hæmatologiske sygdomme som modtager intensiv kemoterapi og /eller strålebehandling.

Herlev Hospital, Dept. of haematology (L121)0 个研究点开始时间: 2009年1月19日最近更新: 2016年12月5日

适应症

试验速览

暂无简介。

•Patients of 18 years or over who have been referred to Department of Haematology (L), Herlev Hospital for treatment of haematological malignancies by means of the following regimes: high dose methotrexat, high dose vepesid, high dose melphalan, BEAM, induction treatment by ALL, as well as patients treated with radiation therapy of the oral cavity.
•Only patients who have signed an informed consent form will be included.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Pregnant women and nursing mothers (women of child bearing age must apply secure contraceptive measures)
•2. No acceptance from patient
•3. Known hypersensitivity to bismuth or other tablet content
•4. Severe renal insufficiency with creatinin clearance below 25 ml/min.
•5. Patients receiving other treatment for protection of the mucous membrane except cryo treatment of the oral cavity (lumps of ice in the mouth)
•6. Other experimental treatment within the previous 4 weeks.

发起方

Herlev Hospital, Dept. of haematology (L121)